Swanson Mark S, Sinha Uttam K
Department of Otolaryngology - Head and Neck Surgery, University of Southern California, 1520 San Pablo St, Suite 4600, Los Angeles, CA 90033, USA.
Oral Oncol. 2015 Jan;51(1):12-5. doi: 10.1016/j.oraloncology.2014.10.010. Epub 2014 Oct 28.
Targeted immunotherapy promoting anti-tumor T-cell activity has shown improved survival and durable objective responses in advanced melanoma patients. Data is mounting that concurrent use of ipilimumab and nivolumab has a more pronounced effect than either as monotherapy. Although no completed clinical trials exist for their use in head and neck cancer, preclinical data suggests these therapies would be beneficial in head and neck malignancies as well. Their role in head and neck cancer management is an ongoing research effort.
促进抗肿瘤T细胞活性的靶向免疫疗法已在晚期黑色素瘤患者中显示出存活率提高和持久的客观缓解。越来越多的数据表明，同时使用伊匹木单抗和纳武单抗比单药治疗具有更显著的效果。尽管目前尚无关于它们用于头颈癌的完整临床试验，但临床前数据表明这些疗法对头颈恶性肿瘤也有益。它们在头颈癌治疗中的作用仍在持续研究中。
